Betaver - instructions for use, dose, side effects, contraindications

Active substance:
Betahistine dihydrochloride	8 mg	16 mg
Excipients:
Microcrystalline cellulose	42 mg	84 mg
Lactose (milk sugar)	34.8 mg	69.6 mg
Corn starch	19.5 mg	39 mg
Povidone (polyvinylpyrrolidone)	7.3 mg	14.6 mg
Carboxymethyl starch sodium (primogel)	3.6 mg	7.2 mg
Talc	3.6 mg	7.2 mg
Silica colloidal dioxide (aerosil)	1.2 mg	2.4 mg

Description:

Tablets are white or almost white in color, flat-cylindrical, with a bevel (for a dosage of 8 mg) and with a facet and a risk (for a dosage of 16 mg).

Pharmacotherapeutic group:Histamine drug

ATX: & nbsp

N.07.C.A.01 Betagistin

Pharmacodynamics:

Betagistin acts mainly on histamine H₁- and H₃receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic effects on H₁receptors of the vessels of the inner ear, as well as indirectly through exposure to H₃-receptors improves microcirculation and permeability of the capillaries of the inner ear, normalizes the pressure of the endolymph in the labyrinth and cochlea. At the same time betagistin increases blood flow in the basilar artery.

Has a pronounced central effect, being an inhibitor of H₃receptors of the nuclei of the vestibular nerve. Normalizes the conductivity in the neurons of the vestibular nuclei at the level of the brainstem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in noise in the ears, and improvement in hearing in the event of a decrease in it.

Pharmacokinetics:

Absorbed quickly, the connection with plasma proteins is low. The maximum concentration in the blood plasma after 3 hours. Half-life after 3-4 hours. It is almost completely excreted by the kidneys in the form of a metabolite (2-peridylacetic acid) for 24 hours.

Indications:

- Treatment and prevention of vestibular vertigo of various origin;

- fromindromes, including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;

- bolezn / Ménière syndrome.

Contraindications:

- Hypersensitivity to any of the components of the drug;

- pregnancy and lactation (due to insufficient data).

Carefully:

Peptic ulcer disease of the duodenum (including in the anamnesis), pheochromocytoma, bronchial asthma. These patients should be observed regularly during the treatment period.

Dosing and Administration:

Inside, with food.

Betaver 8 mg: 1-2 tablets 3 times a day.

Betaver 16 mg: 1 / 2-1 tablet 3 times a day.

Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment.

Duration of drug intake is selected individually.

Side effects:

Gastrointestinal disorders.

In very rare cases, there have been reports of hypersensitivity reactions from the skin (rash, itching, urticaria), Quincke's edema.

Overdose:

Symptoms: nausea, vomiting, there may be seizures when taking a dose of more than 640 mg.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Cases of interaction or incompatibility with other drugs are unknown.

Effect on the ability to drive transp. cf. and fur:

Betaver has no sedative effect and does not affect the ability to drive a car or work on machines and mechanisms.

Form release / dosage:

Tablets, 8 and 16 mg.

Packaging:

10 tablets per contour cell pack.

3 contour packs with instructions for use in a pack of cardboard.

For 30 tablets in a jar of orange glass. Each jar along with instructions for use in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

4 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-002346

Date of registration:12.03.2012 / 02.10.2015

Expiration Date:Unlimited

The owner of the registration certificate:VEROPHARM SA VEROPHARM SA Russia

Manufacturer: & nbsp

VEROPHARM SA Russia

Representation: & nbspVEROPHARM, AO VEROPHARM, AO Russia

Information update date: & nbsp24.01.2017

Illustrated instructions

Instructions

Betavert® (Betaver®)